Tuesday, February 9, 2021 - 10:00PM Asia/Singapore
NEW YORK, February 9, 2021 - Pfizer today announced a partnership with IDA Foundation, an independent social enterprise providing essential medicines to low-and middle-income countries, to provide equitable access to quality cancer treatments in almost 70 developing countries across Latin America, Asia, Africa and the Western Pacific region. The supply agreement means that millions more patients will now have the potential to access innovative chemotherapy medicines for multiple types of cancer.
Developing countries currently bear over 60% of the global cancer burden and account for 70% of cancer deaths. By providing sustainable access to Pfizer’s oncology portfolio, the agreement enables governments and non-governmental organizations (NGO) in developing countries to work toward improving the quality and quantity of available treatments and increase budgets for cancer care and treatment.
“I am proud to announce this landmark partnership, which brings us one step closer to our objective of ensuring cancer patients everywhere have sustainable access to the quality treatments they need,” said Michelle Akande, Vice President, Global Health Partnerships at Pfizer. “We are continuously expanding our efforts to meet the needs of patients in parts of the world where access remains a challenge. Partnerships remain central to how we work, and we continue to identify new partners from all sectors who share our vision and commitment to improve health system and patient level outcomes, and provide long-term access to innovative, life-saving medicines to everyone, everywhere.”
The partnership with IDA Foundation builds on Pfizer’s long-standing collaboration with the American Cancer Society and the Clinton Health Access Initiative, which has provided access to Pfizer’s portfolio of quality oncology treatments in 11 countries in sub-Saharan Africa. Countries that access products through the agreements save an average of 56 percent on the cost of the medicines.
“With approximately 70% of deaths from cancer occurring in low- and middle-income countries, it is an urgent health burden which needs to be addressed. We believe this collaboration with Pfizer can help to bridge a gap and make quality essential medicines affordable and accessible in countries where they are needed most,” said Wendy Eggen, CEO of IDA Foundation.
The new partnership gives access to Pfizer’s portfolio of sterile injectable treatments to an additional 62 countries not previously served by existing market access agreements. This includes 11 low- and middle-income markets in the WHO Western Pacific area, which has the highest cancer mortality rate in the world.
The supply agreement covers 18 essential cancer treatments and 30 formulations, including options for the treatment of breast, cervical and prostate cancer, which are among the most frequent types of cancer in developing countries and are often highly treatable.
The partnership represents a new milestone in the work of Pfizer’s Global Health Partnerships team, which collaborates with the world’s leading health and development organizations to create commercial models that enable sustainable access to established and innovative medicines and vaccines in low- and middle-income countries.
With a portfolio of 3000 health products in over 130 countries, IDA Foundation is an independent social enterprise providing essential medicine and medical goods to healthcare organizations worldwide at an equitable price.
About the Partnership
The partnership is effective immediately and supply of medicines under the agreement is expected to commence in February 2021.
The countries covered by the agreement are: Venezuela, Paraguay, Uruguay, Bolivia, West Indies, Haiti, Suriname, Guyana in Latin America; Cambodia, Myanmar, Laos in Asia; Cook Islands, Fiji, Kiribati, Micronesia, Nauru, Niue, Samoa, Salomon Islands, Tonga, Tuvalu, Vanuatu in the Western Pacific; and Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic (CAR), Chad, Comoros, Democratic Republic of Congo, Cote d'Ivoire, Djibouti, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Guinea, Guinea-Bissau, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Sudan, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe in Africa.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com.In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
# # # # #
 International Agency for Research on Cancer (IARC). ‘World Cancer Report 2014’. Available at: https://publications.iarc.fr/Non-Series-Publications/World-Cancer-Repor…
 World Health Organization (WHO). ‘Cancer Factsheet’. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer
 International Agency for Research on Cancer (IARC). ‘Estimated age-standardized mortality rates (World) in 2020, all cancers, both sexes, all ages’. Data available at: https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020&mode=popula…